Equities

Immunome Inc

IMNM:NAQ

Immunome Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)15.29
  • Today's Change-0.21 / -1.35%
  • Shares traded1.48m
  • 1 Year change+110.61%
  • Beta1.7794
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1382049
Total Receivables, Net00.85--
Total Inventory------
Prepaid expenses6.561.487.41
Other current assets, total------
Total current assets1452357
Property, plant & equipment, net3.640.970.86
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.10----
Total assets1492458
LIABILITIES
Accounts payable3.312.403.08
Accrued expenses7.834.936.65
Notes payable/short-term debt000
Current portion long-term debt/capital leases----0
Other current liabilities, total11----
Total current liabilities227.339.73
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total6.830.060.01
Total liabilities297.399.74
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital343133127
Retained earnings (accumulated deficit)(223)(116)(79)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.02----
Total equity1201748
Total liabilities & shareholders' equity1492458
Total common shares outstanding431212
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.